Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

导出原文传递

翻译打印收藏纠错

作者： Zielinski, Christoph ^[1] ; Lang, Istvan ^[2] ; Beslija, Semir ^[3] ; Kahan, Zsuzsanna ^[4] ; Inbar, Moshe J. ^[5] ; Stemmer, Salomon M. ^[6] ; Anghel, Rodica ^[7] ; Vrbanec, Damir ^[8] ; Messinger, Diethelm ^[9] ; Brodowicz, Thomas

作者单位： Med Univ Vienna, Gen Hosp, Clin Div Oncol, Dept Med 1, Waehringer Guertel 18-20, A-1090 Vienna ^[1] Natl Inst Oncol, Rath Gyorgy 7-9, H-1122 Budapest, Hungary ^[2] Univ Sarajevo, Ctr Clin, Inst Oncol, Bolnicka 27, Sarajevo 71000, Bosnia & Herceg ^[3] Med Univ Zagreb, Univ Hosp Zagreb Rebro, Dept Med Oncol, Kispaticeva 12, Zagreb 10000, Croatia ^[4] Univ Szeged, Dept Oncotherapy, Koranyi Fasor 12, H-6720 Szeged, Hungary ^[5] IST GmbH, Soldnerstr 1, D-68219 Mannheim, Germany ^[6] Rabin Med Ctr, Davidoff Ctr, Kaplan St, IL-49100 Petah Tiqwa, Israel ^[7] Tel Aviv Sourasky Med Ctr, Oncol Div, 6 Weizman St, IL-64239 Tel Aviv, Israel ^[8] Univ Med & Pharm Bucharest, 252,Sect 2, Bucharest 022328, Romania ^[9]

关键词 Capecitabine bevacizumab metastatic breast cancer predictive factor phase III fluoropyrimidine

发布时间 2017-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交